registry, as of 2026-11-03
https://clinicaltrials.gov/study/NCT07890376
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes. Overall status NOT_YET_RECRUITING. Phases PHASE2. Lead sponsor Eli Lilly and Company. Enrollment 460. Conditions Obesity; Overweight. The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condit
ClinicalTrials.gov NCT07890376 protocol and results modules
registry, as of 2026-08-19Stale
https://clinicaltrials.gov/study/NCT06945419
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes. Overall status COMPLETED. Phases PHASE1. Lead sponsor Eli Lilly and Company. Enrollment 219. Conditions Healthy; Overweight; Obesity; Type 2 Diabetes. The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body. Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks
ClinicalTrials.gov NCT06945419 protocol and results modules
Registry NCT07890376
Phase Phase 2
Status Not yet recruiting
Enrollment 460
LY4086940 Dose 1
Comparator placebo
Population Obesity; Overweight
LY4086940 Dose 2
Comparator placebo
Population Obesity; Overweight
LY4086940 Dose 3, Titration Schedule A
Comparator placebo
Population Obesity; Overweight
LY4086940 Dose 3, Titration Schedule B
Comparator placebo
Population Obesity; Overweight
LY4086940 Dose 4
Comparator placebo
Population Obesity; Overweight
LY4086940 Dose 5
Comparator placebo
Population Obesity; Overweight
LY4086940 Dose 6, Titration Schedule A
Comparator placebo
Population Obesity; Overweight
LY4086940 Dose 6, Titration Schedule B
Comparator placebo
Population Obesity; Overweight
LY4086940 Dose 6, Titration Schedule C
Comparator placebo
Population Obesity; Overweight
Placebo
Population Obesity; Overweight
Registry NCT06945419
Phase Phase 1
Status Completed
Enrollment 219
Start 2025-04-23
Primary completion 2026-08-05
Study completion 2026-08-05
Catalyst Primary completion. 2026-08-05. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.Stale
Part A: LY4086940 Single Dose (Healthy Participants)
Comparator placebo
Population Healthy; Overweight; Obesity; Type 2 Diabetes
Part A: Placebo Single Dose (Healthy Participants)
Population Healthy; Overweight; Obesity; Type 2 Diabetes
Part A: LY4086940 Multiple Dose (Healthy Participants)
Comparator placebo
Population Healthy; Overweight; Obesity; Type 2 Diabetes
Part A: Placebo Multiple Dose (Healthy Participants)
Population Healthy; Overweight; Obesity; Type 2 Diabetes
Part B: LY4086940 Multiple Dose (Participants with Overweight or Obesity)
Comparator placebo
Population Healthy; Overweight; Obesity; Type 2 Diabetes
Part B: Placebo Multiple Dose (Participants with Overweight or Obesity)
Population Healthy; Overweight; Obesity; Type 2 Diabetes
Part C: LY4086940 Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity)
Comparator placebo
Population Healthy; Overweight; Obesity; Type 2 Diabetes
Part C: Placebo Multiple Dose (Japanese/Chinese Participants with Overweight or Obesity
Population Healthy; Overweight; Obesity; Type 2 Diabetes
Part D: LY4086940 Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity)
Comparator placebo
Population Healthy; Overweight; Obesity; Type 2 Diabetes
Part D: Placebo Multiple Dose (Participants with Type 2 Diabetes with Overweight or Obesity)
Population Healthy; Overweight; Obesity; Type 2 Diabetes
Part E (Open-Label): LY4086940 Single Dose (Healthy Participants)
Comparator placebo
Population Healthy; Overweight; Obesity; Type 2 Diabetes